Dendritic cell populations that inhibit gvhd
Patent Information
- Application Number
- HK62026126467
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Priority Date
- 2023-03-13
- Filing Date
- 2026-07-21
- Publication Date
- 2026-09-25
- Estimated Expiration
- 2044-03-12
Smart Images
Figure 00000000_0000_ABST
Abstract
Description
Abstract This article provides compositions and methods for the prevention, treatment or suppression of graft-versus-host disease (GvHD) comprising dendritic cells (DCs) exposed to extracellular polysaccharides (EPS).
Claims
WHAT IS CLAIMED IS:
1. A method to prevent, treat or inhibit graft vs host disease (GvHD) comprising administering exopolysaccharide (EPS) exposed dendritic cells (DCs) to a subject in need thereof so as to prevent, treat or inhibit GvHD in said subject.
2. A method to decrease at least one symptom of graft vs host disease (GvHD) comprising administering to a subject in need thereof exopolysaccharide (EPS) exposed dendritic cells (DCs) so as to decrease at least one symptom in said subject.
3. A method to prolong the survival of a subject with graft vs host disease (GvHD) comprising administering exopolysaccharide (EPS) exposed dendritic cells (DCs) to a subject in need thereof so as to prolong the survival of said subject.
4. A method to downregulate expression of activation markers (e.g., CD80 and / or CD86), upregulate expression inhibitory molecules (e.g., PD-L1 and / or PD-L2), inhibit activation of alloreactive T cells or a combination thereof comprising administering exopolysaccharide (EPS) exposed dendritic cells (DCs) to a subject in need thereof so as to downregulate expression of activation markers (e.g., CD80 and / or CD86), upregulate expression of inhibitory molecules (e.g., PD-L1 and / or PD-L2), inhibit activation of alloreactive T cells or a combination thereof.
5. The method of any one of claims 1 to 4, wherein the GvHD is acute GvHD (aGvHD).
6. The method of any one of claims 1 to 4, wherein the GvHD is chronic GvHD (cGvHD).
7. The method of any one of claims 1 to 6, wherein the EPS exposed DCs are administered more than once (e.g., over a period of days, weeks, months, years).
8. The method of claim 7, wherein the EPS exposed DCs are administered with hematopoietic stem cells (HSCs).
9. The method of any one of claims 1 to 8, wherein at least one other therapeutic agent to treat GvHD is administered to said subject.
10. The method of any one of claims 1 to 9, wherein the subject is human.
11. A method to generate tolerogenic dendritic cells (DCs) comprising: a) providing CD34+hematopoietic cells (HSCs), b) culturing the CD34+cells of a) with a combination of SCF, Flt3L, TPO, IL6, StemRegenin 1 (SRI) so as to expand the CD34+cells, c) culturing the cells of b) with GM-CS and IL4 so as to further expand the cells and generate DCs in vitro, d) contacting the cells of c) with exopolysaccharide (EPS), and e) optionally cry opreserving the cells of d), wherein the EPS is optionally removed from the cells of d) prior to cryopreserving.
12. The method of claim 11, where in the HSCs are obtained from umbilical cord blood.
13. The method of claim 11 or 12, wherein the cells are cryopreserved before c), after c) and / or after d).
14. The method of any of claims 11 to 13, further comprising wherein the EPS is removed from the cells of e) prior to cryopreserving or administering.